Vida Ventures (Boston)
Edit

Vida Ventures (Boston)

https://www.vidaventures.com/
Last activity: 25.07.2024
Active
Invests in categories: DevelopmentDrugBioTechMedtechPlatformHealthTechTechnologyPersonalProductCar
Vida Ventures is a next-generation life sciences investment firm founded in 2017 by a group of scientists, physicians, entrepreneurs and investors passionate about building and funding breakthroughs in biomedicine. Together we form an independent, bold investment group bound together by a simple word – life. Our mission is to bring science to life and advance transformative biomedical innovations that have the potential to make a meaningful difference for patients. Vida has a bicoastal presence and currently manages approximately $295 million.
News
128
Portfolio
34
Persons
17
Mentions
18
Location: United States, Massachusetts, Boston
Employees: 11-50
Investment Type: Venture Capital
Investment Stage: Series A; Series B

Portfolio 34

DateNameWebsiteTotal RaisedLocation
13.04.2024Capstan Th...capstantx.com$175MUnited Sta...
13.04.2024InduProinduprotx.com$85MUnited Sta...
13.04.2024Peloton Th...pelotontherapeutics.com$40.2M-
03.11.2023Avalyn Pha...avalynpharma.com$210.5MUnited Sta...
22.03.2022Affini-Taffinittx.com$175MUnited Sta...
10.02.2022Alterome T...alterome.com$232MUnited Sta...
01.02.2022Centessa P...centessa.com$250MUnited Kin...
01.02.2022Homology M...homologymedicines.com$187MUnited Sta...
30.11.2021Protego Bi...protegobiopharma.com$51M-
30.11.2021Quanta The...quantatx.com$110.7M-
Show more

Persons 17

DateFirst NameLast NameTitleLinkedInLocation
-ChanelEnzAccounting...-
-RajulJain, M.D.Managing D...-
-ArieBelldegrun...Co-Founder...-
-Jean-Phili...(JP) Kouak...Chief Fina...-
-ScottGarlandVenture Pa...-
-VictoriaStephensSenior Con...-
-AlexLoftis, Ph...Senior Ass...-
-ArjunGoyal, M.D...Co-Founder...-
-AlexMejiaExecutive ...-
-HelenS. Kim, M....Senior Man...-
Show more

News 128

DateTitleDescription
03.04.2024Alterome Therapeutics Raises $132 Million in Series B Financing-
26.03.2024Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure-
20.03.2024Capstan Therapeutics Announces $175M Oversubscribed Series B Financing-
21.02.2024ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Study of Inhaled mRNA-Based Genetic Medicine, RCT2100, for the Treatment of Cystic Fibrosis-
16.02.2024Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis-
10.02.2024Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering-
30.01.2024AVROBIO and Tectonic Therapeutic Announce Merger-
04.01.2024Kyverna’s KYV-101 Receives U.S. FDA Clearance for Treatment of Patients With Refractory, Progressive Multiple Sclerosis in the KYSA-7 Phase 2 Trial-
03.01.2024Aktis Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference-
03.01.2024ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia-
Show more

Mentions in press and media 18

DateTitleDescription
25.07.2024Canadian Startups Surge: Clio and Third Arc Bio Lead the Charge** **** In the world of startups, the spotlight often shines brightest on Silicon Valley. Yet, this week, Canadian startups have taken center stage, proving that innovation knows no borders. Two companies, Clio and Third Arc Bio, have made headl...
23.07.2024Third Arc Bio Launches with Oversubscribed $165 Million Series A Financing to Deliver Superior Biologics for Solid Tumors and Inflammatory & Immunology (I&I) Diseases-- Company formed and originally seeded by Omega Funds, Series A financing with exceptional syndicate led by Vida Ventures -- World-class leadership team led by Peter F. Lebowitz, MD, PhD, Sanjaya Singh, PhD, and Joe Erhardt, PhD, well-posi...
23.07.2024Third Arc Bio launches with $165M to address unmet needs in oncology and autoimmunityThe company was founded by executives from Johnson & Johnson Third Arc Bio is a company that says its on mission to deliver transformational therapies for solid tumors and inflammatory & immunology diseases through the use of multif...
23.05.2024Venture Leaders Biotech 2024: Captains Blog by Maria Van Dongen, CEO of Allegria Therapeutics, and Gabriel Liguori, CEO of TissueLabsVenture Leaders Biotech 2024: Captains Blog by Maria Van Dongen, CEO of Allegria Therapeutics, and Gabriel Liguori, CEO of TissueLabs 23.05.2024 12:30, Rita Longobardi linkedIn facebook twitter instagram youtube --> In mid-May, the ten V...
22.03.2022Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations-
04.07.2021Vida Ventures Closes Fund III, At $825MVida Ventures Leadership (from left to right): Rajul Jain, Stefan Vitorovic, Arjun Goyal, Arie Belldegrun, Jean-Philippe Kouakou-Zebouah, Helen S. Kim (Photo: Business Wire) Vida Ventures, a Los Angeles, CA- and Boston, MA-based life scienc...
24.06.2021Andreessen Horowitz gears up for more mega crypto betsThis is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content The gender pay gap and your investment strategies From Refinitiv Venture capitalists...
24.06.2021Andreessen Horowitz gears up for more mega crypto betsThis is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content Change your marketer experience and unleash growth for your business From Optimizely...
24.06.2021Vida Ventures Closes $825 Million Vida III Fund to Advance Transformative Biomedical Innovations-
01.08.2019Vida Ventures Closes $600 Million Vida II Fund to Support Life Science Innovation-
Show more

Reviews 0

Sign up to leave a review

Sign up Log In